Monitoring the KMT2A gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation

Documenti analoghi

• Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation
  di: Xiaolu Zhu, et al.
  Pubblicazione: (2025)
• Clinical features and prognostic model for viral encephalitis after allogeneic haematopoietic stem cell transplantation
  di: Jin Wu, et al.
  Pubblicazione: (2024)
• Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
  di: Francesca Perutelli, et al.
  Pubblicazione: (2025)
• The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation
  di: Xu‐Ying Pei, et al.
  Pubblicazione: (2025)
• Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation
  di: Tingting Zhang, et al.
  Pubblicazione: (2024)